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Abstract
Background: Low-density lipoprotein (LDL) cholesterol lowering is a primary goal in clinical
management of patients with cardiovascular disease, but traditional cholesterol levels may not
accurately reflect the true atherogenicity of plasma lipid profiles. The size and concentration of
lipoprotein particles, which transport cholesterol and triglycerides, may provide additional
information for accurately assessing cardiovascular risk. This study evaluated changes in plasma
lipoprotein profiles determined by nuclear magnetic resonance (NMR) spectroscopy in patients
participating in a prospective, nonrandomized lifestyle modification program designed to reverse
or stabilize progression of coronary artery disease (CAD) to improve our understanding of
lipoprotein management in cardiac patients.
Results: The lifestyle intervention was effective in producing significant changes in lipoprotein
subclasses that contribute to CAD risk. There was a clear beneficial effect on the total number of
LDL particles (-8.3%, p < 0.05 compared to matched controls), small dense LDL particles (-9.5%, p
< 0.05), and LDL particle size (+0.8%; p < 0.05). Likewise, participants showed significant
improvement in traditional CAD risk factors such as body mass index (-9.9%, p < 0.01 compared
to controls), total cholesterol (-5.5%, p < 0.05), physical fitness (+37.2%, p < 0.01), and future risk
for CAD (-7.9%, p < 0.01). Men and women responded differently to the program for all clinically-
relevant variables, with men deriving greater benefit in terms of lipoprotein atherogenicity. Plasma
lipid and lipoprotein responses to the lifestyle change program were not confounded by lipid-
lowering medications.
Conclusion: In at risk patients motivated to participate, an intensive lifestyle change program can
effectively alter traditional CAD risk factors and plasma lipoprotein subclasses and may reduce risk
for cardiovascular events. Improvements in lipoprotein subclasses are more evident in men
compared to women.
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Background
The causal role of high blood cholesterol in the pathogen-
esis of coronary artery disease (CAD) is well established.
A large body of research indicates that plasma cholesterol
levels are important risk factors for CAD, and a number of
clinical trials have shown that aggressive cholesterol man-
agement in patients with heart disease leads to significant
reductions in cardiovascular events [1,2]. At present, the
amount of cholesterol carried by lipoprotein particles, in
particular low-density lipoprotein (LDL) particles, is an
important parameter for estimating CAD risk; thus, clini-
cal strategies for patients with established disease typically
focus on lowering LDL as a primary goal of therapy. Tra-
ditional cholesterol levels, however, may not accurately
reflect the true atherogenicity of plasma lipid profiles
because patients with similar cholesterol levels may have
differences in the number and size of lipoprotein particles
that transport cholesterol and triglycerides and thus may
differ in terms of CAD risk.
A more accurate way to assess cardiovascular risk may be
to measure the size and concentration of lipoprotein par-
ticles [3]. Early studies of lipoprotein subclass distribu-
tions using gradient gel electrophoresis found that
increased CAD risk was associated with small, dense LDL
(sdLDL, pattern B) particles [4-6]. More recent studies
using nuclear magnetic resonance (NMR) spectroscopy,
which exploits spectral differences between lipoprotein
subspecies to directly quantify particle size and concentra-
tion, have shown that small LDL particles and a greater
number of LDL particles are associated with CAD devel-
opment and progression in the general population and in
patients with coronary disease [7-10]. Because lipoprotein
characteristics may be important for assessing cardiovas-
cular risk [11], it is important to understand how lipopro-
teins respond during cardiovascular treatment and
prevention programs to identify interventions that favora-
bly modify atherogenic lipid profiles.
Lifestyle interventions have shown the substantial health
benefits of a low fat diet, increased physical activity, and
stress management in reducing traditional risk factors for
cardiovascular disease [12,13] and in slowing or reversing
the progression of coronary atherosclerosis [14,15]. Car-
diac patients who follow healthy lifestyles often show
notable improvements in standard lipid profiles, high-
lighted by dramatic reductions in LDL- and total choles-
terol [16-19]. Although lipoprotein profiles can be
effectively modified by statin or fibrate therapy [20,21],
little is known about how lipoprotein subclasses respond
to non-pharmacological CAD interventions. The purpose
of this study was to evaluate the impact of an intensive
risk factor modification program on lipoprotein sub-
classes defined by NMR spectroscopy and to improve our
understanding of lipoprotein management in patients
with heart disease. Our objectives were to (1) measure
changes in physiological risk factors for CAD throughout
a year-long healthy lifestyle intervention, (2) assess
response of NMR-measured lipoprotein subclasses and
relate changes to improvement in vascular health, and (3)
determine possible benefits of the program in terms of
cardiovascular risk.
Methods
The Institutional Review Board at Windber Medical
Center approved the research protocol and informed con-
sent documents. All subjects enrolled in the program vol-
unteered to participate and gave written informed
consent. Data reporting follows recommendations of the
Transparent Reporting of Evaluations with Nonrand-
omized Designs (TREND) group [22].
Subjects
The study population consisted of 73 Caucasian partici-
pants (34 women and 39 men) who completed a prospec-
tive, nonrandomized intervention designed to stabilize or
reverse progression of CAD through dietary changes, exer-
cise, stress management, and group support. Entry criteria
were (1) a diagnosis of CAD, which included stable
angina, angioplasty, evidence of ³ 50% luminal narrow-
ing on coronary angiogram, acute myocardial infarction,
bypass surgery, or stent placement; or (2) two or more
CAD risk factors: high blood pressure (BP) – systolic pres-
sure > 140 mm Hg or diastolic pressure > 90 mm Hg, high
total cholesterol (> 200 mg/dL), physician diagnosed dia-
betes, obesity defined as body mass index (BMI) ³ 30, or
family history of heart disease in parents or siblings.
Prospective participants were recruited by advertisements
in regional news media and were accepted into the pro-
gram only with physician approval. Motivation to commit
to following the guidelines of the program for the entire
year was part of the acceptance criteria and was assessed
by in-depth interviews before admission. Because tobacco
use is a significant risk factor for CAD, and breaking a nic-
otine addiction often requires interventions beyond the
scope of the lifestyle change program, patients were
required to successfully abstain from smoking for at least
three months prior to enrollment.
Control participants (n = 73; 34 women and 39 men)
receiving only standard care from their primary physicians
were matched to lifestyle participants based on gender,
age at baseline within a five-year window, and CAD status
(diagnosis of CAD or risk factors) using a prospective indi-
vidual matching strategy similar to that described by
Charpentier et al. [23]. The objective of this method is to
achieve a balanced distribution of risk factors between
intervention and control patients in nonrandomized clin-
ical trials. Control subjects underwent examinations atLipids in Health and Disease 2009, 8:26 http://www.lipidworld.com/content/8/1/26
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baseline, 12 weeks, and 52 weeks, but did not participate
in the lifestyle change program or receive healthy lifestyle
information.
Intervention
Details on the Dr. Dean Ornish Program for Reversing
Heart Disease have been published elsewhere [24,25]. The
intervention consists of four components: (1) a very low
fat vegetarian diet (< 10% of calories from fat) with
emphasis on whole grains, fruits, vegetables, legumes, and
soy products; (2) 180 minutes/week within an individu-
ally determined heart rate range of moderate aerobic exer-
cise such as walking, rowing, or water aerobics; (3) one
hour of stress management each day, which may include
a combination of yoga poses, deep breathing, imagery,
meditation, and relaxation; and (4) two one-hour group
support sessions per week for the first 12 weeks and one
group session per week during the remainder of the year.
During the first 12 weeks, program staff met with patients
two times each week to maximize adherence to the pro-
gram guidelines and assess any changes in disease status
or adverse events. During the remainder of the program,
patients came to the center once a week for an hour of
stress management and an hour of group support.
Patients were primarily self-directed but met with pro-
gram staff one time each week to review status and
progress. From January 2004 to August 2008, approxi-
mately 36 patients or controls were enrolled each year in
separate cohorts of ~12 individuals per cohort.
All participants in the program were required to submit a
personal awareness log each week, which summarized for
each day their diet (daily fat, carbohydrate, protein intake
calculated as a percentage of calories), exercise (frequency
and duration), stress management (frequency and dura-
tion), and group support (frequency of meeting attend-
ance). For each component, adherence to the program
guidelines was calculated as a percentage of the recom-
mended goals achieved by each patient. Program staff
reviewed the compliance forms weekly and provided
immediate feedback to patients on their progress and
guidance for improving adherence in specific areas as nec-
essary.
Throughout the year-long program, we experienced a
drop-out rate of ~32% (n = 46) among participants in the
healthy lifestyle program. In addition, 22 participants
were excluded from the analysis because no suitable
matching control was identified.
Lipoprotein subclass measurements
Clinical examinations were performed at baseline, 12
weeks, and 52 weeks to assess changes in CAD risk factors
and to collect blood for standard lipid and lipoprotein
analysis. All examinations were conducted by physicians
or trained personnel and followed identical protocols.
Fasting blood samples were obtained at each examination
and placed directly on ice. Within one hour of collection,
plasma aliquots were isolated from whole blood by cen-
trifugation and stored at -80°C. Lipoprotein subclass pro-
files were measured on freshly-thawed plasma samples by
NMR spectroscopy at LipoScience (Raleigh, NC, USA) fol-
lowing previously published methods [26]. Concentra-
tions of VLDL and LDL (including IDL) subclasses in
nmol/L units and HDL subclasses in mmol/L units were
obtained from the measured amplitudes of the distinct
lipid methyl group NMR signals they emit. The estimated
diameters of the nine measured subclasses were as fol-
lows: large VLDL (> 60 nm), medium VLDL (35–60 nm),
small VLDL (27–35 nm), IDL (23–27 nm), large LDL
(21.2–23.0 nm), small LDL (18.0–21.2 nm), large HDL
(8.8–13.0 nm), medium HDL (8.2–8.8 nm), and small
HDL (7.3–8.2 nm). Total LDL particle concentrations
reflect the sum of the IDL, large LDL, and small LDL sub-
class concentrations, while the sum of large, medium, and
small HDL subclass concentrations give total HDL particle
concentration. Weighted-average VLDL, LDL, and HDL
particle sizes were calculated by summing the diameter of
each subclass multiplied by its relative mass percentage as
estimated by the amplitude of its methyl NMR signal.
A random sample of patients, selected to assess reproduc-
ibility of lipoprotein particle measurements, showed coef-
ficients of variation (CV) between 78 blind duplicate
samples that were similar to previously reported values
[26]. Coefficients of variation for clinically important
lipoprotein parameters were: total LDL particles (6.9%),
small LDL particles (13.7%), LDL size (1.5%), large HDL
particles (8.1%), HDL size (0.6%), and large VLDL/chy-
lomicrons (18.4%).
Physiological measures
Participants in the lifestyle change program and prospec-
tive controls were interviewed to collect information on
age, gender, ethnicity, smoking status, cardiovascular his-
tory, and medication use. Height and weight measure-
ments were used to calculate BMI. Blood pressure was
recorded using a mercury sphygmomanometer on the arm
of seated, relaxed subjects. General endurance was deter-
mined by a graded treadmill exercise test that estimated
the volume of oxygen each participant could consume
(VO2 max; ml/kg/min) based on exercise intensity, dura-
tion, and body weight (Bruce score) [27]. Assays for stand-
ard high-density lipoprotein (HDL) cholesterol, total
cholesterol, and triglycerides were conducted using the
AEROSET™ multi-task clinical chemistry system (Abbott
Laboratories, Abbott Park, IL, USA).Lipids in Health and Disease 2009, 8:26 http://www.lipidworld.com/content/8/1/26
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Cardiovascular risk
Future CAD risk was calculated for each subject as the
probability of experiencing a subsequent coronary event
in patients with cardiovascular disease or an initial event
in disease-free participants within the next four years [28].
The Framingham risk models use separate formulas for
men and women. Individuals were excluded from the risk
calculations (n = 8) if their CAD status changed due to a
cardiac event during the year or if they had missing data
in one or more fields needed to calculate CAD risk.
Statistical analysis
Statistical analyses were conducted using SPSS version
15.0; p values < 0.05 were considered statistically signifi-
cant. Prior to analysis, Lilliefors test was used to determine
normality of the outcome data, and natural log-transfor-
mations were used for variables with non-normal distri-
butions. Potential differences in baseline measures
among the lifestyle program and control group cohorts
were examined by analysis of variance (ANOVA). As no
significant cohort-to-cohort variability at baseline was
detected, all intervention and control cohorts were respec-
tively combined in subsequent analyses.
Baseline characteristics between lifestyle participants and
control subjects were compared by an independent sam-
ples Student-t test, or by a nonparametric Mann-Whitney
U test if the data remained non-normally distributed after
natural log transformation. Statistical comparisons of
changes in CAD risk factors at 12 weeks and 52 weeks
between the intervention and control groups were done
using repeated-measures ANOVA with group (interven-
tion versus control) as the between-subjects factor. Inde-
pendent samples t-tests (two-tailed) then identified
differences in CAD risk factor response from baseline to
week 52 between the intervention and control groups. For
each outcome variable, differences in response between
men and women were assessed by two-factor repeated
Table 1: Lipoprotein subclass measurements and physiological variables at baseline by case/control status
Variable Controls (n = 73) Participants (n = 73) p valuea
Lipoprotein subclassb
VLDL and chylomicron particle concentrations (nmol/L)
Total VLDL and chylomicron particles 82.0 ± 45.3 87.5 ± 39.6 0.15
Large VLDL and chylomicron particles 4.6 ± 6.3 8.2 ± 6.8 < 0.01c
Medium VLDL particles 38.1 ± 28.5 39.7 ± 25.7 0.50c
Small VLDL particles 39.3 ± 19.9 39.7 ± 17.2 0.90
LDL particle concentrations (nmol/L)
Total LDL particles 1253 ± 367 1437 ± 477 0.01
Large LDL particles 337 ± 211 251 ± 218 < 0.01c
Intermediate LDL particles 45.8 ± 38.5 72.6 ± 50.2 < 0.01c
Small LDL particles 870 ± 434 1113 ± 478 < 0.01
HDL particle concentrations (mmol/L)
Total HDL particles 34.7 ± 6.7 32.1 ± 5.6 0.01
Large HDL particles 6.4 ± 3.5 4.6 ± 3.4 < 0.01
Medium HDL particles 5.2 ± 4.9 5.9 ± 4.8 0.25c
Small HDL particles 23.1 ± 7.0 21.7 ± 5.8 0.17
Mean particle sizes (nm)
VLDL size 50.6 ± 9.0 55.6 ± 10.4 < 0.01
LDL size 20.7 ± 0.9 20.2 ± 0.8 < 0.01
HDL size 8.9 ± 0.4 8.6 ± 0.3 < 0.01
Physiological variablesd
Age 60.0 ± 7.8 60.3 ± 8.0 0.79
Body mass index (kg/m2) 28.2 ± 3.7 34.0 ± 7.0 < 0.01
Systolic blood pressure (mm Hg) 133 ± 17 136 ± 17 0.12c
Diastolic blood pressure (mm Hg) 78.9 ± 9.2 80.8 ± 9.8 0.50c
HDL-cholesterol (mg/dl) 50.5 ± 13.7 43.7 ± 13.1 < 0.01c
LDL-cholesterol (mg/dl) 111 ± 33 111 ± 39 0.64c
Total cholesterol (mg/dl) 191 ± 42 193 ± 47 0.82
Triglycerides (mg/dl) 148 ± 100 189 ± 99 < 0.01
Physical fitness (Bruce score) 10.4 ± 2.8 6.6 ± 2.2 < 0.01
Framingham risk (× 100) 7.4 ± 6.8 10.7 ± 8.5 0.02c
Values are presented as mean ± SD. a: tested by independent samples Student-t test, b: there was no missing data, c: tested by a nonparametric 
Mann-Whitney U test because data was not normally distributed after LN transformation, d: there was < 3.2% missing data.Lipids in Health and Disease 2009, 8:26 http://www.lipidworld.com/content/8/1/26
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measures ANOVA (baseline, 12 weeks, and 52 weeks)
with group and gender within groups as the between-sub-
jects factors, using a Bonferroni adjustment for multiple
comparisons by time point, group, and gender within
group. As above, independent samples t-tests (two-tailed)
compared baseline to week 52 changes between groups,
by gender. To examine the potential confounding effects
of lipid-lowering medications on response to the pro-
gram, a sub-group analysis was conducted that included
only participants who continued taking the same brand
and dosage of lipid-lowering medications as well as those
not taking any lipid-lowering drugs.
Results
Baseline characteristics of participants in the lifestyle
change program and matched controls are presented in
Table 1. Intervention subjects differed from controls for
many lipoprotein subclass measurements and several
Changes in LDL particle concentrations during the lifestyle change program Figure 1
Changes in LDL particle concentrations during the lifestyle change program. All participants were included in the 
initial analyses (left panels), then stratified by gender (right panels). Improvement: decrease in total and small LDL particles; 
increase in LDL size.
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physiological variables despite the prospective matching
strategy, which matched controls to participants based on
gender, age at entry, and CAD status. For clinically rele-
vant measures that may contribute to CAD risk, partici-
pants in the program usually had a more atherogenic risk
factor profile.
Lipoprotein subclass measurements did not differ signifi-
cantly between participants who completed the lifestyle
intervention (graduates) and those who dropped out. For
traditional CAD risk factors, dropouts tended to be
younger (55.0 ± 11.2 versus 60.3 ± 8.0; p < 0.01) and have
lower systolic BP (130.1 ± 18.8 versus 136.5 ± 17.0; p <
0.05) than graduates. Participants excluded from the anal-
ysis due to non-matching were older (64.6 ± 10.8 com-
pared to 60.3 ± 8.0; p < 0.05) and had larger HDL particles
(8.8 ± 0.4 versus 8.6 ± 0.3; p < 0.05) and higher HDL-cho-
lesterol (49.6 ± 11.1 versus 43.7 ± 13.1; p < 0.01) than
participants included in the study.
Effects of lifestyle changes on lipoproteins
The lifestyle intervention led to significant changes in
NMR-defined lipoprotein subclasses, in particular, clini-
cally important LDL variables that contribute to CAD risk
(Figure 1). There was a clear beneficial effect on the total
number of LDL particles, which decreased 8.3% overall in
participants (p < 0.05 compared to controls). Likewise,
sdLDL particles, which have been associated with CAD
Table 2: Changes in lipoprotein subclass measurements and physiological variables by case/control status
Controls (n = 73) Participants (n = 73)
Variable Baseline Week 12 Week 52 % change Baseline Week 12 Week 52 % change Between group
p valuea
Lipoprotein subclassb
VLDL and chylomicron particles (nmol/L)
Tot VLDL/chylo 82.0 ± 45.3 80.2 ± 42.6 81.9 ± 47.2 -0.2 87.5 ± 39.6 96.2 ± 43.3 88.5 ± 45.3 +1.2 0.84
Lg VLDL/chylo 4.6 ± 6.3 5.2 ± 6.2 4.5 ± 5.4 -1.2 8.2 ± 6.8 4.7 ± 5.3c 5.8 ± 7.0d -29.4 0.03
Medium VLDL 38.1 ± 28.5 37.4 ± 24.3 37.8 ± 29.5 -0.9 39.7 ± 25.7 49.8 ± 31.8c 42.0 ± 28.6 +6.0 0.50
Small VLDL 39.3 ± 19.9 37.6 ± 22.1 39.6 ± 19.9 +0.6 39.7 ± 17.2 41.7 ± 18.7 40.7 ± 21.7 +2.6 0.80
LDL particles (nmol/L)
Total LDL 1253 ± 367 1242 ± 422 1249 ± 414 -0.4 1437 ± 477 1291 ± 445c 1317 ± 452d -8.3 0.04
Large LDL 337 ± 211 315 ± 191 317 ± 208 -5.8 251 ± 218 215 ± 152 263 ± 174 +4.5 0.24
Intermed LDL 45.8 ± 38.5 55.6 ± 56.2 43.1 ± 44.6 -5.8 72.6 ± 50.1 50.6 ± 43.4c 47.3 ± 46.3c -34.9 < 0.01
Small LDL 870 ± 434 872 ± 445 888 ± 457 +2.1 1113 ± 478 1025 ± 432 1007 ± 470d -9.5 0.04
HDL particles (mmol/L)
Total HDL 34.7 ± 6.7 35.2 ± 6.1 35.2 ± 6.4 +1.7 32.1 ± 5.6 29.0 ± 5.0c 32.3 ± 5.9 +0.6 0.64
Large HDL 6.4 ± 3.5 6.7 ± 3.3 6.5 ± 3.5 +1.4 4.6 ± 3.4 4.3 ± 2.2 5.2 ± 2.9 +12.7 0.19
Medium HDL 4.9 ± 4.6 5.2 ± 5.1 4.5 ± 4.5 -8.6 5.6 ± 4.7 4.2 ± 4.1c 5.2 ± 5.3 -7.8 0.70
Small HDL 23.1 ± 7.0 23.0 ± 7.0 24.2 ± 6.7 +4.6 21.7 ± 5.8 20.6 ± 4.7 22.1 ± 6.9 +2.2 0.49
Mean particle sizes (nm)
VLDL size 50.6 ± 9.0 51.8 ± 8.2 50.9 ± 7.5 +0.6 55.6 ± 10.4 48.2 ± 8.6c 50.2 ± 9.5c -9.7 < 0.01
LDL size 20.7 ± 0.9 20.7 ± 0.8 20.7 ± 0.8 -0.2 20.2 ± 0.8 20.2 ± 0.6 20.4 ± 0.7 +0.8 0.03
HDL size 8.8 ± 0.4 8.9 ± 0.4 8.8 ± 0.4 -0.4 8.6 ± 0.3 8.7 ± 0.3 8.7 ± 0.4d +1.0 < 0.01
Physiological variablese
BMI 28.2 ± 3.7 28.0 ± 3.9 28.3 ± 3.8 +0.4 34.0 ± 7.0 31.4 ± 6.3c 30.7 ± 6.6c -9.9 < 0.01
Systolic BP 133 ± 17 128 ± 15d 126 ± 13d -5.4 136 ± 17 122 ± 14c 127 ± 16c -6.6 0.55
Diastolic BP 78.9 ± 9.2 78.1 ± 8.0 77.3 ± 8.4 -2.0 80.8 ± 9.8 72.6 ± 8.3c 76.0 ± 9.4d -6.0 0.08
HDL 50.5 ± 13.7 51.9 ± 12.7 48.1 ± 13.5d -4.9 43.7 ± 13.1 37.5 ± 9.0c 42.8 ± 10.3 -2.1 0.26
LDL 111 ± 33 110 ± 35 112 ± 36 +1.0 111 ± 39 96 ± 34c 107 ± 34 -3.9 0.23
Tot cholesterol 191 ± 42 192 ± 45 191 ± 46 +0.2 193 ± 47 167 ± 44c 183 ± 43d -5.5 0.03
Triglycerides 148 ± 100 158 ± 140 152 ± 89 +2.8 189 ± 99 167 ± 73 168 ± 97 -11.3 0.05
Bruce 10.4 ± 2.8 10.6 ± 2.7 10.3 ± 2.8 -1.4 6.6 ± 2.2 8.5 ± 2.3c 9.0 ± 2.7c +37.2 < 0.01
Fram risk 7.2 ± 6.7 6.8 ± 6.5 7.2 ± 7.2 +0.6 11.0 ± 8.6 10.2 ± 8.5d 10.1 ± 7.8d -7.9 < 0.01
Values are presented as mean ± SD; differences between table values and calculated values are due to rounding; % change = week 0–52. a: p values 
resulting from independent samples t-tests (two-tailed) of Baseline to Week 52 changes in Ornish participants compared to the control group, b: 
there was no missing data, c: values at Week 12 and Week 52 were significantly different from Baseline at p < 0.001 based on repeated-measures 
ANOVA with time point as the within-subjects factor and cohort type as the between-subjects factor, d: values at Week 12 and Week 52 were 
significantly different from Baseline at p < 0.05 based on repeated-measures ANOVA with time point as the within-subjects factor and cohort type 
as the between-subjects factor, e: there was < 4.2% missing data.Lipids in Health and Disease 2009, 8:26 http://www.lipidworld.com/content/8/1/26
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risk in several studies, decreased 9.5% during the program
(p < 0.05 versus controls). Lifestyle changes also were
effective in increasing both HDL (+1.0%; p < 0.01) and
LDL (+0.8%; p < 0.05) particle size, while decreasing very-
low-density lipoprotein (VLDL) size (-9.7%; p < 0.01) and
large VLDL and chylomicron concentrations (-29.4%; p <
0.05) (Table 2).
Lifestyle changes and traditional risk factor response
Participation in the lifestyle change program had signifi-
cant beneficial effects on traditional (physiological) CAD
risk factors (Table 2). Patients achieved on average a 9.9%
reduction in BMI by the end of the year-long program (p
< 0.01 compared to controls), a 5.5% reduction in total
cholesterol (p < 0.05), and a 37.2% increase in their phys-
Table 3: Changes in selected lipoprotein subclass measurements and standard plasma lipid profiles by gender
Controls (n = 73) Participants (n = 73)
Variable Gender Baseline Week 12 Week 52 % change Baseline Week 12 Week 52 % change Between
group
p valuea
VLDL 
particles
Large VLDL/
chylomicrons
F 5.7 ± 7.7 6.1 ± 7.4 5.0 ± 6.0 -12.4 7.9 ± 7.0 5.9 ± 6.2 8.1 ± 8.5 +3.0 0.62
M 3.6 ± 4.5 4.4 ± 5.0 4.1 ± 4.9 +14.5 8.4 ± 6.8 3.6 ± 4.1b 3.7 ± 4.7b -55.9 < 0.01
LDL 
particles
Total LDL 
particles
F 1364 ± 388 1376 ± 500 1347 ± 475 -1.3 1478 ± 497 1356 ± 460 1388 ± 516 -6.1 0.42
M 1156 ± 323 1126 ± 302 1163 ± 335 +0.6 1401 ± 463 1234 ± 430c 1256 ± 385c -10.4 0.03
Small LDL 
particles
F 902 ± 491 914 ± 548 924 ± 534 +2.4 1076 ± 565 1046 ± 485 1048 ± 568 -2.6 0.63
M 843 ± 382 834 ± 334 857 ± 381 +1.7 1145 ± 393 1006 ± 385c 972 ± 368c -15.1 < 0.01
LDL size F 20.9 ± 0.9 20.9 ± 0.9 20.8 ± 0.9 -0.4 20.5 ± 0.9 20.4 ± 0.7 20.5 ± 0.8 0.0 0.62
M 20.6 ± 0.8 20.5 ± 0.7 20.5 ± 0.7 0.0 20.0 ± 0.6 20.1 ± 0.6 20.3 ± 0.6c +1.6 < 0.01
HDL 
particles
Large HDL 
particles
F 7.4 ± 3.7 7.8 ± 3.5 7.4 ± 3.8 -0.3 5.8 ± 4.1 5.1 ± 2.6c 5.7 ± 3.1 -2.6 0.83
M 5.4 ± 3.0 5.7 ± 2.8 5.6 ± 2.9 +3.3 3.5 ± 2.1 3.7 ± 1.4 4.7 ± 2.7c +34.9 0.03
HDL size F 9.0 ± 0.4 9.0 ± 0.4 8.9 ± 0.4 -0.7 8.8 ± 0.3 8.7 ± 0.2 8.8 ± 0.3 +0.4 0.07
M 8.7 ± 0.4 8.8 ± 0.4 8.7 ± 0.4 0.0 8.5 ± 0.2 8.6 ± 0.2c 8.6 ± 0.4c +1.6 0.03
Lipid 
profiles
HDL-
cholesterol
F 55.9 ± 12.6 57.2 ± 11.8 52.9 ± 13.0 -5.3 49.2 ± 15.5 40.7 ± 10.5b 45.5 ± 9.3c -7.4 0.77
M 45.9 ± 13.0 47.3 ± 11.7 43.8 ± 12.6 -4.5 38.9 ± 8.1 34.8 ± 6.6c 40.4 ± 10.6 +3.8 0.03
Tot 
cholesterol
F 211 ± 35 213 ± 44 208 ± 43 -1.4 206 ± 48 181 ± 42b 197 ± 43 -4.5 0.42
M 173 ± 40 173 ± 38 177 ± 44 +2.0 182 ± 45 156 ± 43b 171 ± 41 -6.4 0.02
Triglycerides F 164 ± 105 181 ± 193 157 ± 85 -3.9 192 ± 100 188 ± 83 199 ± 117 +3.9 0.54
M 134 ± 95 139 ± 62 148 ± 94 +9.8 187 ± 100 149 ± 59c 140 ± 65c -24.9 < 0.01
Values are presented as mean ± SD; differences between table values and calculated values are due to rounding; % change = week 0–52. There were 
34 women and 39 men in each group, there was no missing data. a: p values resulting from independent samples t-tests (two-tailed) of Baseline to 
Week 52 changes for female Ornish participants compared to female controls and male Ornish participants compared to male controls, b: values at 
Week 12 and Week 52 were significantly different from Baseline at p < 0.001 based on repeated measures ANOVA (time point was the within-
subjects factor, cohort type and gender within cohorts were the between-subjects factors) using a Bonferroni adjustment for multiple comparisons 
by time point, group, and gender within group, c: values at Week 12 and Week 52 were significantly different from Baseline at p < 0.05 based on 
repeated measures ANOVA (time point was the within-subjects factor, cohort type and gender within cohorts were the between-subjects factors) 
using a Bonferroni adjustment for multiple comparisons by time point, group, and gender within group.Lipids in Health and Disease 2009, 8:26 http://www.lipidworld.com/content/8/1/26
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ical fitness score (p < 0.01). No significant differences in
response at 52 weeks between cases and controls were
observed for HDL- and LDL-cholesterol. Although pro-
gram participants showed a significant decrease (-14%; p
< 0.001) in HDL-cholesterol from baseline to 12 weeks,
by the end of the year HDL recovered to near baseline lev-
els. Benefits of the program were also evident in changes
in future risk for CAD – average decrease in Framingham
risk among participants was 7.9% compared to a 0.6%
increase in controls (p < 0.01).
Gender differences in response
For variables that showed a significant difference in out-
come between participants and controls, we used repeated
measures ANOVA by group and gender nested within
group to investigate gender specific responses. Gender was
not a significant factor for changes in lipoprotein sub-
classes from baseline to 52 weeks among controls; how-
ever, men and women participating in the program
responded differently for all clinically-relevant variables
(Table 3). Among female participants, changes in clini-
cally-important lipoprotein measures did not differ signif-
icantly from women in the control group, and were not
different from baseline after 52 weeks. In contrast, men
following the healthy lifestyle appeared to derive greater
benefit than women in terms of lipoprotein atherogenic-
ity (Figure 1). Specifically, total LDL particle concentra-
tions (-10.4%; p < 0.05 compared to control men), sdLDL
(-15.1%; p < 0.01 versus men in the control group), LDL
particle size (+1.6%; p < 0.01), and large VLDL (-55.9%; p
< 0.001) all improved significantly among men who par-
ticipated in the program. Similar patterns of change also
Table 4: Effects of lipid-lowering medication changes on selected variables after 52 weeks
All participants No medication changes
% change (wk 0–52) % change (wk 0–52)
Variable Gender Controls
(n = 73)
Ornish
(n = 73)
Between group
p valuea
Controls
(n = 47)
Ornish
(n = 56)
Between group
p valuea
VLDL particles
Large VLDL and chylomicrons F -12.4 +3.0 0.62 +4.9 +4.6 0.95
M +14.5 -55.9b < 0.01 +26.9 -54.9b < 0.01
LDL particles
Total LDL particles (nmol/L) F -1.3 -6.1 0.42 -1.2 -4.2 0.63
M+ 0 . 6 - 1 0 . 4 c 0.03 +8.1 -3.8 0.02
Small LDL particles (nmol/L) F +2.4 -2.6 0.63 +1.3 -0.9 0.86
M+ 1 . 7 - 1 5 . 1 c < 0.01 +13.2 -8.6 < 0.01
LDL size (nm) F -0.4 0.0 0.62 -0.4 0.0 0.70
M 0.0 +1.6c < 0.01 -0.6 +1.5c < 0.01
HDL particles
Large HDL particles (mmol/L) F -0.3 -2.6 0.83 +0.3 -4.2 0.71
M+ 3 . 3 + 3 4 . 9 c 0.03 -1.2 +31.6 0.04
HDL size (nm) F -0.7 +0.4 0.07 -0.8 +0.4 0.15
M 0.0 +1.6c 0.03 -0.5 +0.8 0.08
Lipid profiles
HDL-cholesterol F -5.3 -7.4c 0.77 -6.5 -9.0c 0.83
M -4.5 +3.8 0.03 -4.3 +3.3 0.08
Total cholesterol F -1.4 -4.5 0.42 -0.2 -3.2 0.47
M +2.0 -6.4 0.02 +5.7 -2.9 < 0.01
Triglycerides F -3.9 +3.9 0.54 +5.1 +5.4 0.91
M+ 9 . 8 - 2 4 . 9 c < 0.01 +10.1 -23.5c < 0.01
There were 34 female and 39 male participants in the control and intervention groups, 19 female and 28 male controls with no medication changes, 
30 female and 26 male participants with no medication changes. a: p values resulting from independent samples t-tests (two-tailed) of Baseline to 
Week 52 changes for female Ornish participants compared to female controls and male Ornish participants compared to male controls, b: percent 
changes from Baseline to Week 52 were significant at p < 0.001 based on repeated measures ANOVA (time point was the within-subjects factor, 
cohort type and gender within cohorts were the between-subjects factors) using a Bonferroni adjustment for multiple comparisons by time point, 
group, and gender within group, c: percent changes from Baseline to Week 52 were significant at p < 0.05 based on repeated measures ANOVA 
(time point was the within-subjects factor, cohort type and gender within cohorts were the between-subjects factors) using a Bonferroni 
adjustment for multiple comparisons by time point, group, and gender within group.Lipids in Health and Disease 2009, 8:26 http://www.lipidworld.com/content/8/1/26
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were apparent for large HDL particles (+34.9%; p < 0.05)
and HDL size (+1.6%; p < 0.05).
For physiological variables, both men and women
showed a significant decrease in BMI and increase in phys-
ical fitness scores (p < 0.001) compared to controls after
one year. Similar to lipoproteins, however, HDL-choles-
terol (+3.8%; p < 0.05), triglycerides (-24.9%; p < 0.001),
and total cholesterol (-6.4%; p < 0.05) improved signifi-
cantly in male participants compared to male controls,
but no significant changes compared to controls were
seen in women.
Effects of lipid-lowering medications
Lipid-lowering therapy did not have significant effects on
lipid and lipoprotein responses to the lifestyle change
program. There were 56 participants (77%) and 47 con-
trols (64%) who were not taking lipid-lowering drugs or
whose medication levels did not change during the study.
Results of the sub-group analysis examining lipid and
lipoprotein responses in these patients were largely simi-
lar to analyses encompassing all participants (Table 4).
When controlling for changes in medications, some vari-
ables were no longer significantly different from baseline
at 52 weeks, but still showed significant improvement
compared to controls with no changes in lipid-lowering
medications.
Discussion
Participants who completed a comprehensive year-long
lifestyle change program designed to reverse or stabilize
progression of CAD showed significant improvement in
traditional cardiovascular risk factors and a significant
decrease in future cardiovascular risk. The lifestyle inter-
vention also was effective in improving lipoprotein pro-
files that contribute to CAD risk. When analyses were
stratified by gender, men appeared to derive greater vascu-
lar health benefit than women due to significant changes
in important lipoprotein subclasses, including decreases
in LDL particle number, sdLDL particles, and large VLDL,
and increases in HDL and LDL particle size. Women
showed no significant improvement for any of the meas-
ured lipoprotein parameters. Changes in clinically-rele-
vant LDL particle attributes were comparable to other
behavioral and pharmacologic interventions for lipopro-
tein management and were not significantly influenced by
changes in lipid-lowering medications.
Lifestyle modification programs are known to improve
cardiovascular risk profiles through significant reductions
in LDL- and total cholesterol, but the effects of lifestyle
interventions on lipoprotein profiles and vascular health
are not well known. To date, only limited research has
examined the impact of lifestyle behaviors, such as exer-
cise and diet, on lipoprotein subclass distributions. Meta-
analyses suggest that aerobic exercise has modest effects
on blood cholesterol levels [29,30], but can lead to impor-
tant beneficial changes in lipoprotein subfractions,
including a reduction in the number of LDL particles and
an increase in both HDL and LDL particle size [31,32].
Similarly, low-fat – high-carbohydrate diets targeting
weight loss have shown favorable effects on lipoprotein
particle size and distribution [33,34]. When dietary inter-
ventions are used in combination with an exercise regi-
men, patients show significant increases in particle size
and a shift toward larger LDL particles [35].
To make lifestyle interventions more comprehensive, pro-
grams have been developed to focus on numerous aspects
of lifestyle including weight management, physical activ-
ity, nutrition, smoking cessation, and stress management.
These multidisciplinary programs have been shown to
improve modifiable cardiovascular risk factors [16-19],
but effects on lipoprotein profiles are not well known.
Compared to controls receiving usual care, we observed
clear benefit to participants for many of the lipoprotein
parameters measured by NMR spectroscopy. Although
lipoproteins are not used in the Framingham formulas for
determining CAD risk, successful modulation of lipopro-
teins through lifestyle changes may have positive effects
on vascular health not readily apparent from traditional
risk factor profiles.
Lipoproteins play an important role in the development
and progression of atherosclerotic disease because lipo-
protein particles transport cholesterol and triglycerides
throughout the body. In particular, low density lipopro-
teins are the primary carriers of cholesterol in plasma, but
are not readily cleared from the circulation. Longer resi-
dence time in the vasculature leads to increased uptake by
the arterial walls and greater susceptibility to oxidization.
LDL particles modified by oxidation accelerate disease
progression by promoting foam cell formation, inflam-
mation, and endothelial dysfunction [36].
In patients with an atherogenic lipoprotein profile charac-
terized by a high number of LDL particles, an abundance
of sdLDL particles, and small LDL size, the vascular intima
is constantly exposed to high concentrations of lipopro-
teins, which interact with the arterial walls and initiate the
cascade of events leading to atherosclerosis [37]. Numer-
ous studies have shown that the total number of LDL par-
ticles is a strong independent predictor of CAD risk [7-9].
Likewise, an abundance of sdLDL particles (and thus
lower average LDL particle size) is associated with a ~3-
fold increase in risk of heart disease in univariate analyses
(reviewed in [36]). sdLDL particles are thought to be par-
ticularly atherogenic because smaller particles: (1) readily
penetrate arterial tissue [38], (2) are susceptible to oxida-
tion [39], and (3) easily bind to arterial proteoglycans
[40]. For patients with atherosclerotic disease, favorable
changes in lipoprotein subclass distributions mayL
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Table 5: Response of LDL particle number, LDL size, and small LDL particles to pharmacologic and lifestyle interventions
LDL subclassa Trial/Center Intervention Daily dosage(mg) Mean follow-up (weeks) Baseline value ± SD Mean change (%) Reference
Total LDL particles GLAIb rosiglitazone 4/8 24 1368 ± 372 +8.2 [48]
(nmol/L) GLAIb pioglitazone 30/45 24 1394 ± 361 -3.5 [48]
STRRIDEc exercise --- ~35 1456 ± 86d -4.5 [31]
VA-HITe gemfibrozil 1200 ~30 1352 ± 316 -4.6 [21]
JUSMHf bezafibrate 400 4 1722 ± 629 -4.6 [49]
Ornish Programg lifestyle (F) --- 52 1478 ± 497 -6.1
UMCPh exercise --- 24 1436 ± 42d -7.0 [32]
Ornish Programg lifestyle (M) --- 52 1401 ± 463 -10.4
MCi pioglitazone 30 19 1420 ± 74d -10.6 [35]
JUSMHj fenofibrate 200 8 1567 ± 606 -10.9 [50]
COMPLEMENTk pioglitazone 30/45 17 1527 ± 473 -12.4 [51]
VCUl niacin IRm 3000 12 2561 ± 81d -14.1 [52]
DUn low-fat diet --- 24 1759 -14.7 [34]
TJUo niacin ERp 1000 12 1993 -15.0 [53]
MCi diet/exercise --- 19 1216 ± 55d -18.8 [35]
PRINCEq pravastatin 40 12 1540r -19.0r [54]
TJUo niacin ERp 2000 12 2048 -23.0 [53]
PLAC-1s pravastatin 20–40 ~26 1908 ± 304 -24.0 [20]
PLAC-1t pravastatin 40 ~26 1918 ± 292 -25.5 [9]
VCUl atorvastatin 10 12 2562 ± 77d -31.4 [52]
CARDSu atorvastatin 10 26 1572r -31.6r [55]
LDL size CARDSu atorvastatin 10 26 20.6r -0.7r [55]
(nm) Ornish Programg lifestyle (F) --- 52 20.5 ± 0.9 0.0
PLAC-1s pravastatin 20–40 ~26 20.7 ± 0.5 +0.3 [20]
PLAC-1t pravastatin 40 ~26 20.7 ± 0.4 +0.5 [9]
PRINCEq pravastatin 40 12 20.8r +0.5r [54]
STRRIDEc exercise --- ~35 20.8 ± 0.2d +1.0 [31]
UMCPh exercise --- 24 21 ± 0.1d +1.0 [32]
COMPLEMENTk pioglitazone 30/45 17 20.3 ± 0.7 +1.1 [51]
DUn low-fat diet --- 24 20.9 +1.4 [34]
VCUl atorvastatin 10 12 19.8 ± 0.1d +1.5 [52]
MCi diet/exercise --- 19 20.6 ± 0.2d +1.5 [35]
Ornish Programg lifestyle (M) --- 52 20.0 ± 0.6 +1.6L
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GLAIb rosiglitazone 4/8 24 20.1 ± 0.8 +1.6 [48]
TJUo niacin ERp 1000 12 20.0 +2.0 [53]
MCi pioglitazone 30 19 20.3 ± 0.2d +2.0 [35]
TJUo niacin ERp 2000 12 21.0 +2.0 [53]
GLAIb pioglitazone 30/45 24 20.0 ± 0.8 +2.3 [48]
VCUl niacin IRm 3000 12 19.9 ± 0.1d +2.5 [52]
VA-HITe gemfibrozil 1200 ~30 20.4 ± 0.8 +2.5 [21]
JUSMHj fenofibrate 200 8 19.7 ± 0.8 +3.8 [50]
JUSMHf bezafibrate 400 4 19.9 ± 1.0 +3.9 [49]
NEMC/UPSMv torcetrapib 120 4 20.4 ± 0.9 +4.9 [56]
NEMC/UPSMv torcetrapib 120/240 8 20.4 ± 0.8 +7.4 [56]
Small LDL CARDSu atorvastatin 10 26 599r +1.8r [55]
particles 
(nmol/L)
Ornish Programg lifestyle (F) --- 52 1076 ± 565 -2.6
GLAIb rosiglitazone 4/8 24 1142 ± 429 -3.4 [48]
UMCPh exercise --- 24 966 ± 55d -13.4 [32]
Ornish Programg lifestyle (M) --- 52 1145 ± 393 -15.1
COMPLEMENTk pioglitazone 30/45 17 1188 ± 513 -19.3 [51]
VA-HITe gemfibrozil 1200 ~30 967 ± 406 -19.6 [21]
MCi pioglitazone 30 19 1119 ± 95d -20.2 [35]
MCi diet/exercise --- 19 888 ± 75d -27.3 [35]
a: determined by NMR spectroscopy, b: 333 (pioglitazone) or 325 (rosiglitazone) type 2 diabetic men and women with dyslipidemia, following 4-week washout period intervention was divided into 
two 12-week intervals where dosage increased in second interval, subjects instructed to follow American Heart Association Step One diet throughout the intervention, c: Studies of Targeted Risk 
Reduction Interventions through Defined Exercise – 22 sedentary, overweight men and women with mild to moderate dyslipidemia (high-amount – high-intensity exercise group), d: values are 
mean ± SE, e: Veterans Affairs High-Density Lipoprotein Intervention Trial – 515 men with known coronary heart disease, f: Jikei University School of Medicine Hospital – hypertriglyceridemic 
men (22) and women (2), g: 39 men (M) or 34 women (F) with overt CAD or risk factors who participated in the lifestyle change program, h: University of Maryland, College Park – sedentary 
healthy men (42) and women (58), subjects followed the American Heart Association Dietary Guidelines for the General Population prior to and throughout exercise training, i: Mayo Clinic – 
non-diabetic insulin-resistant men (18) and women (19), patients consumed an isocaloric diet for one week prior to baseline and follow-up, j: Jikei University School of Medicine Hospital – 20 
hypertriglyceridemic men, k: 295 (baseline) type 2 diabetic men and women with dyslipidemia who received stable doses of rosiglitazone and statins for > 90 days, at enrollment rosiglitazone was 
discontinued and 30 mg once daily pioglitazone was initiated – at the end of the study, 52% were receiving 30 mg/day, while 48% were receiving 45 mg/day, l: Virginia Commonwealth University – 
53 (atorvastatin) or 48 (niacin) men and women with atherogenic dyslipidemia, treatment followed a 6-week lead-in period on a National Cholesterol Education Program Step One diet, m: 
immediate release (IR), n: Duke University – 60 obese, hyperlipidemic men and women who consumed a low-calorie (1590 kcal/day), low-fat (54 g fat/day) diet for 24 weeks, o: Thomas Jefferson 
University – 21 (1000 mg) or 20 (2000 mg) men and women with primary hypercholesterolemia, treatment followed an 8-week lead-in phase on an American Heart Association Step One diet, p: 
extended release (ER), q: Pravastatin Inflammation/CRP Evaluation study – 256 men and women without overt coronary disease, r: median values, s: Pravastatin Limitation of Atherosclerosis in the 
Coronary Arteries trial – 154 men and women with coronary heart disease, t: Pravastatin Limitation of Atherosclerosis in the Coronary Arteries trial – 130 men and women with coronary heart 
disease, u: Collaborative AtoRvastatin Diabetes Study – 69 type 2 diabetic men and women with modest dyslipidemia who had a previous myocardial infarction, v: New England Medical Center and 
University of Pennsylvania School of Medicine – 10 patients received placebo for four weeks then 120 mg torcetrapib daily for four weeks, 6 patients went on to receive 240 mg torcetrapib daily 
for an additional four weeks.
Table 5: Response of LDL particle number, LDL size, and small LDL particles to pharmacologic and lifestyle interventions (Continued)Lipids in Health and Disease 2009, 8:26 http://www.lipidworld.com/content/8/1/26
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decrease vascular reactivity and endothelial dysfunction,
thereby arresting progression of atherosclerosis. Signifi-
cant reductions in the total number of LDL and sdLDL
particles would minimize the number of atherogenic par-
ticles available to interact with the arterial walls, resulting
in a reduction in foam cell formation and less vascular
inflammation.
Despite evidence that behavioral changes can lead to sig-
nificant improvements in atherogenic lipid profiles, cer-
tain at-risk patients may not show comparable benefit
[41]. Women in particular may not respond favorably to
low-fat diet and exercise regimens in terms of plasma lipid
parameters [42] and may be less compliant than men in
meeting lifestyle program goals [43]. In other studies,
men achieved greater reductions in total cholesterol con-
centrations than women in response to a fat-restricted diet
[44]. Here, men enrolled in the Ornish Program showed a
favorable decrease in LDL particle number, sdLDL con-
centrations, and large VLDL, as well as an increase in HDL
and LDL size; however, comparable changes were not
observed in women. Of all lipoprotein and physiological
variables, women showed significant improvements rela-
tive to controls only for BMI and physical fitness. Our data
thus suggest that men may derive greater vascular health
benefits from a comprehensive lifestyle modification pro-
gram. Interestingly, of the four program components –
diet, exercise, stress management, and group support –
only dietary compliance (%) at 52 weeks differed signifi-
cantly (p < 0.05) between men (96.7 ± 2.6) and women
(94.5 ± 4.9). Thus gender specific differences in lipopro-
tein response to the program may be attributable to
endogenous hormones that affect lipoprotein storage,
transport, and metabolism [45].
Successful stabilization and regression of established
atherosclerotic plaques may be achievable clinical goals,
but many interventions fail to induce regression of
advanced lesions containing necrotic, fibrotic, and calci-
fied tissues because patients cannot achieve the drastic
changes in plasma lipoproteins necessary to stabilize the
plaque environment [46]. Pharmacologic agents are com-
monly used to lower lipoprotein concentrations, but
patients often exhibit tremendous variability in response
to different drugs [47]. Our data suggest that changes in
several LDL particle attributes among participants in the
lifestyle change program were comparable to, or superior
to, responses reported from other behavioral and pharma-
cologic interventions [9,20,21,31,32,34,35,48-56] (Table
5). For example, men participating in the program
showed significant reductions in LDL particle number (-
10.4%) and sdLDL particle concentrations (-15.1%),
which were similar to or exceeded exercise training and
fibrate or thiazolidinedione (TZD) therapy. Fibrates
(gemfibrozil, fenofibrate) are used to modulate plasma
lipids in patients with high cholesterol [57], while TZDs
(pioglitazone, rosiglitazone) are insulin-sensitizing drugs
commonly used to treat non-insulin-dependent diabetes
[58]. Likewise, the increase in LDL size (+1.6%) in male
participants was greater percentage-wise than that attrib-
utable to behavioral interventions or statins (atorvastatin,
pravastatin), which are widely prescribed to lower blood
cholesterol and prevent cardiovascular disease [59].
Conclusion
Lowering LDL cholesterol is crucial to reducing cardiovas-
cular morbidity and mortality [60], but LDL levels alone
do not identify all patients at risk for coronary disease.
Current evidence suggests that in addition to conven-
tional plasma lipids, new measures of lipoprotein concen-
tration, size, and composition may provide additional
information for assessing cardiovascular risk. Therapeutic
modulation of lipoprotein profiles, particularly LDL par-
ticle number and LDL size, appears to be associated with
a significant reduction in CAD risk. Our data indicate that
patients who participate in a lifestyle change program rep-
resent a unique population with a particularly atherogenic
CAD risk factor profile who could benefit most from car-
diovascular risk reduction. The Ornish Program was
highly effective for men in altering traditional CAD risk
factors and plasma lipoprotein profiles, which may reduce
vascular reactivity in patients with established disease as
well as those at high risk for cardiovascular events. Con-
versely, women showed little evidence for improvement
in most physiological variables and no significant changes
in lipoprotein profiles relative to controls. The beneficial
effects of the program on plasma lipids and lipoproteins
in men remained significant when controlling for the
potential confounding effects of lipid-lowering medica-
tions. Additional studies are needed to determine if (1)
improvements in lipoprotein profiles extend beyond one
year and translate into improved clinical outcomes, (2)
the apparent gender difference in lipoprotein response
ultimately leads to improvement in long-term vascular
health, and (3) gender tailored lifestyle prescriptions are
required to confer optimal CAD risk benefit.
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